ERBB2 and breast carcinoma: Pertuzumab was first FDA-approved for first-line metastatic HER2-positive breast cancer in 2012, shortly after results from the groundbreaking CLEOPATRA phase III trial, which compared treatment with docetaxel and trastuzumab with or without pertuzumab.